Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 8/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22965168 | 0.89 | CXCR3 (0.60) | CXCR3KCNH2POLBGRIN2BGRIN1 | |
| SCHEMBL3730330 | 0.89 | CXCR3 (0.55) | CXCR3KCNH2POLBGAALMNA | |
| SCHEMBL3731238 | 0.89 | CXCR3 (0.55) | CXCR3KCNH2POLBGAALMNA | |
| SCHEMBL17854893 | 0.88 | CXCR3 (0.61) | CXCR3KCNH2LMNAMAPT | |
| SCHEMBL3726532 | 0.88 | CXCR3 (0.54) | CXCR3KCNH2POLBGAALMNA | |
| SCHEMBL3735603 | 0.87 | CXCR3 (0.59) | CXCR3KCNH2POLBGAALMNA | |
| SCHEMBL3728657 | 0.87 | CXCR3 (0.53) | CXCR3KCNH2POLBGAALMNA | |
| SCHEMBL3736608 | 0.86 | CXCR3 (0.76) | CXCR3KCNH2POLBGAALMNA | |
| SCHEMBL115730 | 0.84 | CXCR3 (0.56) | CXCR3KCNH2GAALMNACCR1 | |
| SCHEMBL24090409 | 0.84 | GRIN2B (0.44) | CXCR3KCNH2GRIN2BGRIN1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315921-A1 | Compounds and Methods for Modifying iAge | Edifice Health, Inc. (US) | 2021-10-14 | — | — | US | disclosed |
| US-10259807-B2 | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives | IDORSIA PHARMACEUTICALS LTD. (SE) | 2019-04-16 | — | — | US | disclosed |
| EP-3024832-B1 | 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-28 | — | — | EP | disclosed |
| EP-3024832-B1 | 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20160176862-A1 | 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-06-23 | — | — | US | disclosed |
| WO-2015011099-A1 | 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-01-29 | — | — | WO | disclosed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 1561/4885POLB 2678/4885 |
| US-20210315921-A1 | Compounds and Methods for Modifying iAge | LIPG, IFNG, CD40LG | CXCR3 244/4885KCNH2 2867/4885POLB 1558/4885 |
| US-10259807-B2 | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 754/4885POLB 3624/4885 |
| US-20160176862-A1 | 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 754/4885POLB 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.